Switching and withdrawing hormonal agents for castration-resistant prostate cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 12, Issue 1, Pages 37-47
Publisher
Springer Nature
Online
2015-01-07
DOI
10.1038/nrurol.2014.345
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
- (2014) Maria Thadani-Mulero et al. CANCER RESEARCH
- Development of Nomogram to Non-steroidal Antiandrogen Sequential Alternation in Prostate Cancer for Predictive Model
- (2014) Naoto Kamiya et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
- (2014) Raya Leibowitz-Amit et al. PROSTATE
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit
- (2013) E. A. Mostaghel et al. CLINICAL CANCER RESEARCH
- The Mutational Landscape of Prostate Cancer
- (2013) Christopher E. Barbieri et al. EUROPEAN UROLOGY
- No Androgen Withdrawal Syndrome for Enzalutamide: A Report of Disease Dynamics in the Postchemotherapy Setting
- (2013) Christoph A. von Klot et al. EUROPEAN UROLOGY
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
- (2013) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
- (2013) X Yuan et al. ONCOGENE
- Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer
- (2013) Orazio Caffo et al. UROLOGY
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Designer antiandrogens join the race against drug resistance
- (2013) Jatinder S Josan et al. eLife
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- The androgen receptor gene mutations database: 2012 update
- (2012) Bruce Gottlieb et al. HUMAN MUTATION
- Gastric Perforation Secondary to Regression of Lung Adenocarcinoma After Gefitinib Treatment
- (2012) Wei-Pang Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The changing therapeutic landscape of castration-resistant prostate cancer
- (2011) Timothy A. Yap et al. Nature Reviews Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: A single-center experience
- (2010) Takatsugu Okegawa et al. INTERNATIONAL JOURNAL OF UROLOGY
- Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
- (2010) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Antiandrogen withdrawal in castrate-refractory prostate cancer
- (2008) A. Oliver Sartor et al. CANCER
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Pleiotropic functional properties of androgen receptor mutants in prostate cancer
- (2008) Jean-Pierre Bergerat et al. HUMAN MUTATION
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternative Nonsteroidal Antiandrogen Therapy for Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade
- (2008) Hiroyoshi Suzuki et al. JOURNAL OF UROLOGY
- Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor
- (2008) Myles C. Hodgson et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started